Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.42 |
| ▸ | CDC7 | O00311 | 4/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8949906 | 0.84 | MAPT (0.47) | NPSR1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL8949899 | 0.84 | MAPT (0.47) | NPSR1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17204516 | 0.83 | NAPRT (0.49) | CYP19A1NPSR1GAAKMT2AALDH1A1 | |
| SCHEMBL30172789 | 0.83 | NAPRT (0.49) | CYP19A1NPSR1GAAKMT2AALDH1A1 | |
| SCHEMBL17204517 | 0.83 | NAPRT (0.49) | CYP19A1NPSR1GAAKMT2AALDH1A1 | |
| SCHEMBL5643255 | 0.82 | TDP1 (0.45) | NPSR1GAAKMT2AALDH1A1HPGD | |
| SCHEMBL8694090 | 0.82 | MEN1 (0.44) | NPSR1KMT2ALMNAMAPTL3MBTL1 | |
| SCHEMBL8694091 | 0.82 | MEN1 (0.44) | NPSR1KMT2ALMNAMAPTL3MBTL1 | |
| SCHEMBL2891426 | 0.78 | KMT2A (0.44) | CDC7DBF4NAMPTNPSR1KMT2A | |
| SCHEMBL2891423 | 0.78 | KMT2A (0.44) | CDC7DBF4NAMPTNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2931716-B1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | COASY, PLPBP, ACSS2 | CYP19A1 488/4885CDC7 3238/4885DBF4 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.